Free Trial

Twin Securities Inc. Raises Stock Holdings in Amedisys, Inc. (NASDAQ:AMED)

Amedisys logo with Medical background

Twin Securities Inc. raised its stake in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 143.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 29,105 shares of the health services provider's stock after acquiring an additional 17,160 shares during the quarter. Amedisys comprises 1.5% of Twin Securities Inc.'s holdings, making the stock its 11th largest position. Twin Securities Inc. owned 0.09% of Amedisys worth $2,642,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Blue Trust Inc. increased its holdings in shares of Amedisys by 55.1% during the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock worth $34,000 after buying an additional 124 shares in the last quarter. Johnson Financial Group Inc. bought a new stake in shares of Amedisys during the 4th quarter valued at about $55,000. Vestcor Inc acquired a new stake in shares of Amedisys during the 4th quarter worth approximately $73,000. Venturi Wealth Management LLC increased its stake in Amedisys by 397.4% in the fourth quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider's stock valued at $89,000 after purchasing an additional 779 shares in the last quarter. Finally, Covestor Ltd raised its stake in Amedisys by 48.8% during the 4th quarter. Covestor Ltd now owns 1,037 shares of the health services provider's stock worth $94,000 after buying an additional 340 shares during the period. 94.36% of the stock is owned by institutional investors and hedge funds.

Amedisys Stock Performance

Shares of AMED traded up $0.07 during mid-day trading on Friday, hitting $93.63. 20,303 shares of the company traded hands, compared to its average volume of 417,606. The stock has a market cap of $3.07 billion, a price-to-earnings ratio of 37.15, a P/E/G ratio of 1.78 and a beta of 0.96. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. Amedisys, Inc. has a 1 year low of $82.15 and a 1 year high of $98.95. The stock has a 50-day moving average price of $93.34 and a two-hundred day moving average price of $91.63.

Amedisys (NASDAQ:AMED - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share for the quarter, topping the consensus estimate of $1.13 by $0.12. The firm had revenue of $594.78 million for the quarter, compared to analysts' expectations of $597.43 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The business's quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.03 EPS. Equities analysts anticipate that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on AMED. Stephens reissued an "equal weight" rating and set a $101.00 price objective on shares of Amedisys in a report on Tuesday, March 4th. Royal Bank of Canada restated an "outperform" rating and set a $100.00 price target on shares of Amedisys in a research note on Wednesday, April 16th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $100.75.

Get Our Latest Stock Analysis on AMED

About Amedisys

(Free Report)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Further Reading

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Should You Invest $1,000 in Amedisys Right Now?

Before you consider Amedisys, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.

While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Analysts Are Watching These 4 Penny Stocks—You Should Too
Congress Is Pouring Millions Into These 6 Surprising Stocks
3 Dirt-Cheap Stocks in a Market That’s Getting Expensive

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines